Children have a mild course of acute COVID-19 in most of the cases. However, a few non-controlled studies on children present an evaluation of long-term recovery from SARS-CoV-2 infection. Mostly, the studies were conducted on a small sample size with children aged between 0-17 years.
The study aimed to evaluate symptoms and duration of 'long COVID' in children.
Data collection was done through a nationwide cohort study with 37,522 RT-PCR verified SARS-CoV-2 infected children, aged between 0-17 years (response rate 44.9%). Further, the study also had a group of 78,037 children as control (response rate 21.3%). An electronic questionnaire was used to collect data.
It was obtained that symptoms lasting > 4 weeks were common among both SARS-CoV-2 children and controls. However, SARS-CoV-2 infected children with the age of 6-17 years reported symptoms more frequently than the control group (percent difference 0.8%).
The most reported symptoms among pre-school children were
Fatigue Risk Difference (RD) 0.05 (CI 0.04-0.06)
Loss of smell RD 0.01 (CI 0.01-0.01)
Loss of taste RD 0.01 (CI 0.01-0.02)
Muscle weakness RD 0.01 (CI 0.00-0.01)
However, in school children, respiratory problems RD 0.03 (CI 0.03-0.04), dizziness RD 0.02 (CI 0.02-0.03), chest pain RD 0.01 (CI 0.01-0.01) were also observed along with the above-mentioned symptoms.
Furthermore, children in the control group experienced significantly more concentration difficulties, headache, muscle and joint pain, cough, nausea, diarrhea and fever than SARS-CoV-2 infected.
In most of the cases, 'long COVID' symptoms resolve in children within 1-5 months. Therefore, it can be interpreted that long COVID in children is rare and mainly of short duration.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
Why breast cancer survivors don't take their medicine, and what can be done about it.
2.
The Higher the Disability Burden From Disease, the Higher the Suicide Risk
3.
FDA Approves New Drug Combo for RR Multiple Myeloma
4.
Big Gain in PFS With Metastasis-Directed RT for Oligometastatic Pancreatic Cancer
5.
Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC
1.
Revolutionizing Thyroid Cancer: Advances in Molecular Genetics and Personalized Treatment Approaches
2.
HCC Codes in Oncology: Care Optimization in Plexiform Neurofibroma Management
3.
Understanding Mantle Cell Lymphoma Prognosis.
4.
Unveiling the Hidden Dangers of Hand Cancer: How to Protect Yourself
5.
Understanding Evans Syndrome: Causes, Symptoms, and Treatment Options
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
2.
From Relapse to Remission: Mapping the Treatment Journey in Adult R/R-Cell ALL - Part 2
3.
First-Line Maintenance Therapy for Metastatic Urothelial Carcinoma: Bridging Clinical Practice and Trials
4.
Navigating the Complexities of Ph Negative ALL - Part VIII
5.
Navigating the Complexities of Ph Negative ALL - Part XIV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation